The "In Situ Hybridization Market Size, Share & Trends Analysis Report By Technology, By Probe, By Product, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
The global in situ hybridization market size is expected to reach USD 2.42 billion by 2030 and is set to expand at 6.9% CAGR from 2023 - 2030. Situ Hybridization (ISH) is extensively utilized for research and clinical applications of diagnostics. ISH is a popular approach among researchers as it aids in determining the relationship between the distribution of specific nucleic acids and the target gene protein products. Hence, expanding the scope of ISH in applications is accelerating and leading to further research.
The increasing awareness about ISH techniques and their usage encourages researchers to employ the techniques for various applications. For instance, the CEO of MultiplexDX stated in an interview with Elsevier that FISH technology can contribute breakthrough information for early drug development and personalized treatment. A growing number of people in developed countries are opting for personalized treatment owing to an increase in awareness, thus boosting market demand.
Furthermore, reimbursement schemes being made available in developed economies have led to an increase in demand for this diagnosis. The demand continues to increase as the majority of the public can now afford it due to the recent expansion through insurance coverage. For instance, Medicare is the largest market player in the U.S., which provides care for those aged 65 years and above, irrespective of their income and medical history.
Owing to the COVID-19 pandemic, the demand side showcased a positive impact on the ISH market as various researchers employed the technique on COVID-19-infected cells. Research published in July 2020, considered 8 autopsy lungs, 10 kidney biopsies, and 1 placenta from COVID-19-infected patients with ISH assay and RNA probes.
COVID-19 positive results showed in all 8 lungs and the placenta by ISH, but not in the kidney samples. The assay showcases a sensitive and specific technique for detecting the virus from tissue samples. Similarly, Advanced Cell Diagnostics, Inc., introduced RNAscope technology to support COVID-19 research.
The growing strategic initiatives by the companies are anticipated to boost the ISH market growth. Key players are introducing novel products in the market to strengthen their portfolios. For instance, in March 2021, F. Hoffmann-La Roche launched DISCOVERY Green HRP chromogen detection kit to expand the multiplexing capability of in situ hybridization and immunohistochemistry.
On the other hand, molecular diagnostics renders accurate & effective results and has indispensable applications in the field of diagnosis. However, the high manufacturing cost of FISH assays and the high amount of capital required for specialized assembly plants & maintenance of instruments used in FISH imaging are likely to limit revenue generation.
Market Dynamics
Market Drivers
- Rising Prevalence Of Target Disorders
- Technological Advancements In The Field Of In Vitro Diagnostics
- Increasing R&D Investments In In Vitro Diagnostics
Market Restraints
- High Cost Of ISH
- Presence Of An Ambiguous Regulatory Framework
Market Opportunities
- Increasing Awareness About ISH Usage
Market Challenges
-
Highly Skilled Labour-Intensive Product
In Situ Hybridization Market Report Highlights
- By technology, the CISH segment is projected to expand at the fastest growth rate during the forecast period. Since the reagents used in CISH are more stable, the sample can be stored for a longer duration and can be examined multiple times
- By probe, the DNA segment is anticipated to have the fastest growth rate during the forecast period. Owing to the increasing incidence of diseases associated with chromosomal aberrations, such as genetic abnormalities and cancer
- By product, the services segment is anticipated to have the fastest-growing CAGR between 2023 to 2030. Increasing outsourcing to ensure high adherence to quality standards and improve operational functionalities contributes to the lucrative growth
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
2.1 Market Snapshot, 2022
Chapter 3 Market Variables, Trends, & Scope
Chapter 4 Technology Type Business Analysis
4.1 In Situ Hybridization Market: Technology Movement Analysis
4.2 FISH
4.3 CISH
Chapter 5 Probe Business Analysis
5.1 In Situ Hybridization Market: Probe Movement Analysis
5.2 DNA
5.3 RNA
Chapter 6 Product Business Analysis
6.1 In Situ Hybridization Market: Product Movement Analysis
6.2 Instruments
6.3 Kits And Probes
6.4 Software
6.5 Services
Chapter 7 Application Business Analysis
7.1 In Situ Hybridization Market: Application Movement Analysis
7.2 Cancer
7.3 Cytogenetics
7.4 Developmental Biology
7.5 Infectious Diseases
7.6 Others
Chapter 8 End-Use Type Business Analysis
8.1 In Situ Hybridization Market: End-Use Movement Analysis
8.2 Hospital & Diagnostics Laboratories
8.3 CROs
8.4 Academic Institutes
8.5 Others
Chapter 9 Regional Business Analysis
Chapter 10 Competitive Landscape
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Abbott (Abbott Molecular)
- Perkinelmer, Inc.
- Bioview
- Agilent Technologies, Inc.
- Merck Kgaa
- Bio-Rad Laboratories, Inc.
- Oxford Gene Technology Ip Limited
- Leica Biosystems Nussloch Gmbh
- F. Hoffman-La Roche Limited
- Neogenomics Laboratories, Inc.
- Advanced Cell Diagnostics, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/srf63a
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005451/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
